文献速递新发突发、热带与寄生虫病

既往感染或完成疫苗接种者中的猴痘:全球病例系列

Mpox in people with past infection or a complete vaccination course: a global case series.
PubMed 文献 · Lancet Infect Dis · 2023-09-04

该全球病例系列纳入9个国家2022年5月11日至2023年6月30日期间经PCR确诊、且有既往感染或完整接种记录的猴痘病例,共报告37例男男性行为者感染,其中7例再感染、29例完成两剂改良安卡拉-巴伐利亚北欧疫苗接种后感染、1例同时符合两者标准;无死亡、无细菌重复感染,仅1例因颈部坏死性病变住院。

要点

  • 37例既往感染或完成疫苗接种后的猴痘感染中,无死亡、无细菌重复感染。
  • 再感染者初次感染病程较短、黏膜病变较少。
  • 接种后感染者病变少、黏膜受累少、镇痛需求低,2人接受口服替考韦瑞马。

核心结论

  • 再感染和接种后感染的流行病学与2022年疫情其他队列相似,主要为年轻、性活跃的男男性行为者。
  • 再感染和接种后感染的临床特征与结局似乎较2022年病例文献描述的更轻。
  • 与2022年病例系列相比,本研究个体融合性病变更少、黏膜受累更少、镇痛需求更低、住院更少。
  • 自然免疫和疫苗诱导免疫不能完全预防猴痘感染,但在此小系列中病程和严重程度似乎减轻。

研究设计与样本

  • 全球病例系列,由9个国家的国际合作者提供数据。
  • 纳入2022年5月11日至2023年6月30日期间经PCR确诊、且有记录既往感染或接种的猴痘个体。
  • 排除无法确认接种状态、部分免疫或当前多国猴痘疫情前(截止日期2022年5月1日)接种任何剂次的病例。
  • 通过病例报告表格收集感染和接种日期、免疫途径、人口学特征、临床发现、HIV状态、合并性传播感染及疾病严重程度标志物(猴痘严重程度评分系统)。
  • 所有分析均为描述性。

主要发现

  • 报告37例男男性行为者猴痘感染:7例再感染,29例完成两剂间隔合适的改良安卡拉-巴伐利亚北欧疫苗接种后感染,1例同时符合再感染和接种后感染标准。
  • 个体中位年龄36岁(IQR 30-45;范围21-58)。
  • 初次感染后自然免疫者再感染时病程较短、黏膜病变较初次感染少。
  • 接种后感染特征为病变少、黏膜病变少、镇痛需求极低;2人接受口服替考韦瑞马。
  • 总体无死亡、无细菌重复感染,所有个体均在门诊管理,1例因颈部坏死性病变住院。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since May, 2022, a large global outbreak of human mpox (formerly known as monkeypox) has predominantly affected men who have sex with men. The strain responsible, Clade IIb, has mutated substantially from precursors originating from the 2017-18 outbreak in Nigeria. Immunity to smallpox, another orthopoxvirus, via previous infection or vaccination provides lifelong immunity. However, since the 2022 mpox outbreak, recent clusters were described in individuals with presumed immunity through recent infection or vaccination. We aim to describe the epidemiological and clinical characteristics of mpox in individuals with past infection or vaccination to improve the understanding of this disease in the setting of previous immunity. METHODS: In this global case series, international collaborators from nine countries provided data on individuals with PCR-confirmed mpox after documented previous infection or vaccination between May 11, 2022, and June 30, 2023. We excluded cases that could not confirm vaccination status or cases with partial immunisation or any doses received before the current multi-national mpox outbreak (cutoff date May 1, 2022). Data were collected via a case report spreadsheet that reported on dates of infection and vaccination, route of immunisation, demographic characteristics, clinical findings, HIV status, concomitant sexually transmitted infections, and markers of disease severity (mpox severity score system). We describe case epidemiology, clinical course, and mpox severity scores; all analyses were descriptive. FINDINGS: We report mpox infections in 37 gay and bisexual men who have sex with men: seven individuals had mpox reinfections, 29 individuals had mpox infections that occurred after two appropriately spaced Modified Vaccinia Ankara-Bavarian Nordic vaccine courses, and one individual had an infection that met the criteria for both reinfection and infection after vaccination. The median age of individuals was 36 years (IQR 30-45; range 21-58). Those with natural immunity after initial infection had a shorter disease course with less mucosal disease upon reinfection than with their initial infection. Infections post-vaccination were characterised by few lesions, little mucosal disease, and minimal analgesia requirements; two people received oral tecovirimat. Overall, there were no deaths, no bacterial superinfections, and all individuals were managed in the ambulatory clinic with one hospital admission for a necrotising neck lesion. INTERPRETATION: The epidemiology of people with mpox reinfection or infection post-vaccination was similar to other published cohorts during the 2022 outbreak-predominantly young, sexually active gay and bisexual men who have sex with men. Clinical features and outcomes of repeat infection and infection after vaccination appear to be less clinically severe than those described in 2022 case literature. Specifically, compared with the 2022 case series, these individuals in the present study had fewer confluent lesions, less mucosal involvement, reduced analgesia requirement, and fewer admissions. Natural immunity and vaccine-induced immunity are not fully protective against mpox infection. However, in this small series both disease duration and severity appear to be reduced. FUNDING: None.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hazra A, Zucker J, Bell E, et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis. 2023. PMID: 37678309. doi:10.1016/S1473-3099(23)00492-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。